Encore Medical Inc. · NYSE:EMI
Encore Medical — IPO Roadshow (April 2026)
21 slides from Encore Medical's IPO roadshow presentation, Apr 9, 2026
Slide 1: Overview
1 Overview Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to Preliminary Prospectus dated March 24, 2026, Registration Statement No. 333 - 290244 Explanatory Note : This Free Writing Prospectus supersedes and replaces the Free Writing Prospectus previously filed with the SEC on
Slide 2: Free Writing Prospectus
2 Free Writing Prospectus This Free Writing Prospectus relates to the proposed initial public offering of Encore Medical, Inc. (“Encore”, “we”, “us” or “our”). We have filed a registration statement (File No. 333 - 290244), including the preliminary prospectus contained therein, with the U.S. Securi
Slide 3: Forward-Looking Statements
3 Forward - Looking Statements This presentation contains forward - looking statements. In some cases, you can identify these forward - looking statements by words such as “may,” ”might,” ”should,” “would,” “expect,”“plan,”“anticipate,” “intend,” “believe,” “estimate, “predict,” “potential” or “cont
Slide 4: Background
4 Background □ Encore has innovative products for closing septal wall defects (holes in the heart), primarily Patent Foramen Ovale (PFO), a flap - like hole between the atrial chambers of the heart. □ A PFO can enable embolic material (clots) to backflow from the right to left chambers and potential
Slide 5: Encore PFO Closure Device
5 Encore PFO Closure Device High closure rates Small footprint, low profile, minimal use of metal Encore believes it has a superior PFO Closure Device to reduce the risk of ischemic stroke reoccurrence Device Sizes: 20, 25, 30 and 35mm Delivery device e asy to deploy and used for both PFO and ASD
Slide 6: Encore PFO Closure Device: Illustration of PFO procedure
6 Encore PFO Closure Device Illustration of PFO procedure
Slide 7: Encore At-a-Glance
7 Encore At - a - Glance Low profile with minimal metal mass Preserves future treatment options – septal puncture friendly Easy to Deploy 35,000+ implanted devices CE - Marked US FDA Trial underway with favorable trial design Commercial Traction in Europe > $2.5M sales 2025 Limited investment and ti
Slide 8: Encore Competitive Advantage
8 Encore Competitive Advantage Conformable Ease of deployment Low profile Partially or fully retrievable Low metal mass Septal puncture friendly Simple delivery Key Points of Differentiation Encore – PFO Closure Device Abbott – Amplatzer W.L. Gore – Cardioform x x x x x x x x x x x x x Note: Abbott
Slide 9: PFO/Stroke Addressable Market (TAM)
9 PFO/Stroke Addressable Market (TAM) See appendix for citations 795,000 patients suffering strokes 692,000 Ischemic strokes 277,000 cryptogenic strokes 139,000 patients with PFO $1.5B+ market opportunity Strokes annually¹ in the U.S. 87% of these strokes are ischemic² 40% of ischemic strokes have u
Slide 10: PFO/Migraine Market
10 PFO/Migraine Market See appendix for citations 45 Million existing patients suffering migraine headache 18 Million migraine + PFO 12 Million positive responders 11 Million PFO Closures $120B+ market opportunity Migraine sufferers in US 40% of migraine patients have a PFO 68% improve on blood thin
Slide 11: Europe Commercialization Strategy
11 Europe Commercialization Strategy Germany 34% Czech Republic 14% Italy 14% Iraq 13% Portugal 8% Lithuania 5% Spain 4% France 2% Switzerland 2% Hungary <1% Austria 2% Turkey 2% Ukraine <1% □ Sales in 21 countries - adding countries in central Asia and Central and South America □ Leveraging sales n
Slide 12: PFO/Stroke Clinical Strategy
12 PFO/Stroke Clinical Strategy FDA Approved Trial Underway Management believes the Clinical Pathway has been relatively de - risked PerFOrm Pivotal Study x Prospective, multicenter, randomized clinical study x Head - to - head study comparing the Encore device to existing FDA approved PFO devices (
Slide 13: PFO/Migraine Clinical Strategy
13 PFO/Migraine Clinical Strategy FDA Trial Design Encore has the opportunity to be the first approved device for treating PFO related Migraine Headache OUS Trial x Currently conducting PFO/Migraine clinical study in Europe. x Designed to demonstrate the clinical effectiveness of our PFO device for
Slide 14: Intellectual Property Portfolio
14 Differentiated technology with no known IP conflicts Intellectual Property Portfolio Expiration Years Title Patent # Issue Date date Left PFO Device 11,771,411 10/3/2023 2040 15 Occlusion Device with Centering Arm 8,366,741 2/5/2013 2030 5 Right Retrieval Mechanism 7,658,748 2/9/2010 2023 expired
Slide 15: Management team
15 Joseph Marino President & CEO, Director ▪ 30 continuous years of CEO, Chairman, Director of Public Companies ▪ Current Chairman of Encore, Cardia, Inc., and Electro - Sensors (NASDAQ) ▪ Previous Chairman at Applied Biometrics, Inc. Biomedical Dynamics Corporation ▪ Former Department Head, Univers
Slide 16: Non-Management Board Members
16 Todd Johnson Director ▪ Chief Compliance Officer Cedar Point Capital, Board Member, Lifelens Technologies, Former Private Placement Specialist, Stifel Nicolaus, Board Observer RxFunction , Inc. 15+ years experience, fundraising professional Christopher Turnbull Director ▪ Director of Encore Medic
Slide 17: Summary Financials
17 Summary Financials FYE FYE FYE Statement of Operations 12/31/2023 12/31/2024 12/31/2025 Audited Audited Audited Net Sales 1,434,424$ 2,134,528$ 2,585,858$ Cost of goods sold 912,078 1,361,077 1,548,302 Gross profit 522,346 773,451 1,037,556 Percentage 36.4% 36.2% 40.1% Operating Expenses Selling,
Slide 18: Offering Summary
18 Offering Summary $15 million (plus over - allotment) Offering Size: Common Stock Security: 3 million Shares Offered: $5.00 per share Price: 15% Over - Allotment: NYSE American – Ticker EMI Listing: 6.7 million Shares O/S before offering Clinical Trials, Commercial Growth, Debt Reduction, Working
Slide 19: Company Highlights
19 Company Highlights Differentiated PFO closure technology $1.5 B Stroke & 100+ B Migraine opportunity Proven safety and efficacy with 35,000+ implants CE - marked with favorable US FDA Trial underway Attractive margins - OUS sales help fund daily operations Structural heart technologies awarded pr
Slide 20: Thank you!
20 Thank you!
Slide 21: Citations
21 Citations 1) Ischemic strokes (Clots). www.stroke.org. (n.d.). https://www.stroke.org/en/about - stroke/types - of - stroke/ischemic - stroke - clots 2) U.S. Department of Health and Human Services. (2022, February 1). How many people are affected by/at risk for stroke? Eunice Kennedy Shriver Nat